Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU To Sue AstraZeneca Over Vaccine Delivery: Can Either Side Win?

First Ruling Could Come This Week

Executive Summary

The legal challenge is risky for the European Commission, with AZ’s contract only binding it to make ‘best reasonable efforts’ to deliver vaccines to schedule.

You may also be interested in...



AstraZeneca And Sanofi March Ahead With Positive Phase III RSV Data

AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.

Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results

Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.

Curis And Autolus Rise On EHA Abstract Data

Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel